Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 5;134(20):e184171.
doi: 10.1172/JCI184171.

Elexacaftor/tezacaftor/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment

Sarah J Morgan  1 , Ellis Coulter  1 , Hannah L Betts  1 , George M Solomon  2 , John P Clancy  3 , Steven M Rowe  2   3 , David P Nichols  1   3 , Pradeep K Singh  1 ; PROMISE-Micro Study Group
Affiliations

Elexacaftor/tezacaftor/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment

Sarah J Morgan et al. J Clin Invest. .
No abstract available

Keywords: Bacterial infections; Microbiology.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have declared that no conflict of interest exists.

Figures

Figure 1
Figure 1. Sputum microbiology after ETI.
(A) Proportion of participants culture positive for indicated pathogens (includes participants missing data at visit). *P < 0.05 by McNemar’s exact test. (B) Proportion of baseline-positive participants becoming repeatedly negative for indicated pathogen by culture (C) or culture and ddPCR (C&dd); n = number of participants analyzed. (C–H) Culture density in participants who were baseline culture positive for indicated pathogens including (C, E, and G) and not including (D, F, and H) culture-negative samples. Similar differences were apparent between all-data vs. data with culture-negative samples eliminated in by-participant averages (Supplemental Figure 1, C–H). Individual participants are indicated in black, averages in red. The limit of detection = 20 CFU/g. *P < 0.05 vs. baseline; #P < 0.05 vs. 1 month by mixed-effects analysis (C–H).
See this image and copyright information in PMC

References

    1. Nichols DP, et al. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. J Clin Invest. 2023;133(10):e167957. doi: 10.1172/JCI167957. - DOI - PMC - PubMed
    1. Schaupp L, et al. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur Respir J. 2023;62(2):2202153. doi: 10.1183/13993003.02153-2022. - DOI - PubMed
    1. Hisert KB, et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am J Respir Crit Care Med. 2017;195(12):1617–1628. doi: 10.1164/rccm.201609-1954OC. - DOI - PMC - PubMed

MeSH terms